GlassScriptPhysician profile
Andrew Edward Bradberry
NPI 1972954006
$5,473.07
in general payments reported to CMS, 2019-2025
31 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.02 · 2020: $159 · 2021: $720 · 2022: $1,389 · 2023: $918 · 2024: $700 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,177.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,270.40 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $628.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $557.11 | 2022-2025 | Vraylar, Ubrelvy, Synthroid |
| Lilly USA, LLC | $456.46 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $418.19 | 2020-2024 | Nexletol |
| Pfizer INC. | $337.19 | 2020-2025 | |
| Glaxosmithkline, LLC. | $234.62 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $233.33 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $231.09 | 2023-2025 | Caplyta |
| Abbott Laboratories | $140.48 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $111.65 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.23 | 2022-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $97.73 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $91.57 | 2022 | |
| Merck Sharp & Dohme LLC | $90.98 | 2021-2023 | Verquvo, Belsomra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $73.99 | 2021-2023 | |
| Amgen INC. | $45.51 | 2021-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $41.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $39.60 | 2025 | Voquezna |
| Dexcom, INC. | $37.56 | 2024-2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $36.05 | 2024 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $32.91 | 2025 | |
| Boston Scientific Corporation | $26.98 | 2025 | Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $24.65 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $20.02 | 2024 | Spravato |
| Bausch Health US, LLC | $17.64 | 2023 | Aplenzin, Wellbutrin |
| Amarin Pharma, INC. | $17.37 | 2022 | |
| Astellas Pharma US INC | $17.29 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.76 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.66 | 2025 | Keveyis |
| Acerus Pharmaceuticals Corporation | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bradberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.